Yahoo
Shenzhen - Delayed Quote CNY

Hangzhou Tigermed Consulting Co., Ltd (300347.SZ)

49.67 +1.48 (+3.07%)
At close: October 30 at 3:04:13 PM GMT+8
Chart Range Bar
Loading chart for 300347.SZ
  • Previous Close 48.19
  • Open 49.28
  • Bid 49.61 x --
  • Ask 49.70 x --
  • Day's Range 47.72 - 53.39
  • 52 Week Range 35.57 - 67.85
  • Volume 16,831,871
  • Avg. Volume 15,963,252
  • Market Cap (intraday) 42.475B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.47
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.13 (0.25%)
  • Ex-Dividend Date Jul 10, 2026
  • 1y Target Est 59.91

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

www.tigermedgrp.com

11,130

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300347.SZ
12.14%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

300347.SZ
15.70%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

300347.SZ
23.96%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

300347.SZ
69.81%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 2.08B
Earnings 141.11M
Profit Margin 6.77%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B
2B
2B
-20.0%
-10.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

44.00 Low
59.91 Average
49.67 Current
76.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.32%

  • Return on Assets (ttm)

    1.57%

  • Return on Equity (ttm)

    -1.71%

  • Revenue (ttm)

    7.6B

  • Net Income Avi to Common (ttm)

    -404.59M

  • Diluted EPS (ttm)

    -0.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.12B

  • Total Debt/Equity (mrq)

    9.53%

  • Levered Free Cash Flow (ttm)

    720.09M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: